FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170126870> ?p ?o ?g. }

• W2170126870 abstract "AACR Annual Meeting-- Apr 18-22, 2009; Denver, COSHP-2 (also termed PTP1D, PTP2C, PTPL1, SHPTP3 and Syp) is a ubiquitously expressed 68kDa non-transmembrane protein tyrosine phosphatase (PTP) and positively regulates mitogenic signals in receptor tyrosine kinase pathways. In response to stimulation of growth factors, SHP-2 is recruited to their receptors to transduce signals. Oncogenic EGFRvIII is a naturally occurring oncoprotein and is expressed in about 40-50% of human glioblastomas, particular those that arise de novo. This mutated oncoprotein is expressed on the cell surface and constitutively phosphorylated in the absence of EGF. Targeting EGFRvIII for cancer therapy by using monoclonal antibodies or kinase inhibitors is under investigation. However, the intracellular signals activated by oncogenic EGFRvIII are poorly understood. To understand the molecular mechanisms by which this oncoprotein alters transforming phenotypes, and since our previous work indicated that SHP-2 protein tyrosine phosphatase activity modulated EGFRvIII activation and downstream signaling, we examined whether SHP-2 plays a role in EGFRvIII-induced oncogenesis. Ectopic expression of a phosphatase-inactive form of SHP-2, SHP-2 C459S, but not its wild-type SHP-2 or either of two SH2 domain mutants, abrogated transformation of EGFRvIII-expressing U87MG cells in soft agar and in nude mice. Furthermore, shp2 +/- and -/- mouse embryonic fibroblasts (MEFs) could not be transformed by EGFRvIII while shp2 +/+ MEFs displayed a fully transformed phenotype upon introduction of EGFRvIII, again indicating a requirement for functional SHP-2 in EGFRvIII transformation. EGFRvIII expression recruited SHP-2 to the receptor complex and increased endogenous SHP-2 PTPase activity and SHP-2 phosphorylation at Tyr542 in U87MG.EGFRvIII cells. Phosphorylated SHP-2 Tyr542 accumulated in the cellular membrane in parental and EGFRvIII-expressing cells, but only localized to the perinuclear region in EGFRvIII-containing cells by immunofluorescence staining (IF). Activated SHP-2 interacted with focal adhesion kinase (FAK) to further transduce signals and induce a more transformed phenotype . Inhibition of SHP-2 expression by Shp-2 siRNA inhibited cell growth, transformation and altered morphology of EGFRvIII transformed PTEN-deficient U87MG.EGFRvIII and PTEN-intact LN229.EGFRvIII cells. Moreover, the SHP-2 PTPase activity inhibitor NSC-87877 inhibited endogenous SHP-2 activity, Erk phosphorylation and transformation in both GBM cell lines. These data indicate that SHP-2, in particular its PTPase activity, plays a critical role in EGFRvIII-mediated transformation. These data also provide further support that SHP-2 may be a downstream factor of PTEN in human GBMs. Therefore, use of shp-2 siRNAs or SHP-2 inhibitors may represent a potential therapeutic approach for the treatment of human GBMs, in particular primary GBMs that express the EGFRvIII oncoprotein. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-12." @default.
• W2170126870 created "2016-06-24" @default.
• W2170126870 creator A5070796010 @default.
• W2170126870 creator A5071513506 @default.
• W2170126870 date "2009-05-01" @default.
• W2170126870 modified "2023-09-24" @default.
• W2170126870 title "Abstract #LB-12: SHP-2 is a potential therapeutic target for EGFRvIII-transformed human GBMs" @default.
• W2170126870 hasPublicationYear "2009" @default.
• W2170126870 type Work @default.
• W2170126870 sameAs 2170126870 @default.
• W2170126870 citedByCount "0" @default.
• W2170126870 crossrefType "journal-article" @default.
• W2170126870 hasAuthorship W2170126870A5070796010 @default.
• W2170126870 hasAuthorship W2170126870A5071513506 @default.
• W2170126870 hasConcept C101544691 @default.
• W2170126870 hasConcept C11960822 @default.
• W2170126870 hasConcept C121608353 @default.
• W2170126870 hasConcept C153911025 @default.
• W2170126870 hasConcept C178666793 @default.
• W2170126870 hasConcept C31033888 @default.
• W2170126870 hasConcept C42362537 @default.
• W2170126870 hasConcept C502942594 @default.
• W2170126870 hasConcept C54355233 @default.
• W2170126870 hasConcept C555283112 @default.
• W2170126870 hasConcept C62478195 @default.
• W2170126870 hasConcept C81885089 @default.
• W2170126870 hasConcept C85528070 @default.
• W2170126870 hasConcept C86803240 @default.
• W2170126870 hasConcept C95444343 @default.
• W2170126870 hasConcept C97037327 @default.
• W2170126870 hasConceptScore W2170126870C101544691 @default.
• W2170126870 hasConceptScore W2170126870C11960822 @default.
• W2170126870 hasConceptScore W2170126870C121608353 @default.
• W2170126870 hasConceptScore W2170126870C153911025 @default.
• W2170126870 hasConceptScore W2170126870C178666793 @default.
• W2170126870 hasConceptScore W2170126870C31033888 @default.
• W2170126870 hasConceptScore W2170126870C42362537 @default.
• W2170126870 hasConceptScore W2170126870C502942594 @default.
• W2170126870 hasConceptScore W2170126870C54355233 @default.
• W2170126870 hasConceptScore W2170126870C555283112 @default.
• W2170126870 hasConceptScore W2170126870C62478195 @default.
• W2170126870 hasConceptScore W2170126870C81885089 @default.
• W2170126870 hasConceptScore W2170126870C85528070 @default.
• W2170126870 hasConceptScore W2170126870C86803240 @default.
• W2170126870 hasConceptScore W2170126870C95444343 @default.
• W2170126870 hasConceptScore W2170126870C97037327 @default.
• W2170126870 hasLocation W21701268701 @default.
• W2170126870 hasOpenAccess W2170126870 @default.
• W2170126870 hasPrimaryLocation W21701268701 @default.
• W2170126870 hasRelatedWork W187328735 @default.
• W2170126870 hasRelatedWork W1964145991 @default.
• W2170126870 hasRelatedWork W1975082399 @default.
• W2170126870 hasRelatedWork W1988126835 @default.
• W2170126870 hasRelatedWork W1992313470 @default.
• W2170126870 hasRelatedWork W2011392246 @default.
• W2170126870 hasRelatedWork W2014346740 @default.
• W2170126870 hasRelatedWork W2047684340 @default.
• W2170126870 hasRelatedWork W2057437612 @default.
• W2170126870 hasRelatedWork W2057895084 @default.
• W2170126870 hasRelatedWork W2061701210 @default.
• W2170126870 hasRelatedWork W2179507429 @default.
• W2170126870 hasRelatedWork W2521981308 @default.
• W2170126870 hasRelatedWork W2562717999 @default.
• W2170126870 hasRelatedWork W2768126922 @default.
• W2170126870 hasRelatedWork W2922330760 @default.
• W2170126870 hasRelatedWork W2947766558 @default.
• W2170126870 hasRelatedWork W2973596000 @default.
• W2170126870 hasRelatedWork W2990295477 @default.
• W2170126870 hasRelatedWork W2004957691 @default.
• W2170126870 hasVolume "69" @default.
• W2170126870 isParatext "false" @default.
• W2170126870 isRetracted "false" @default.
• W2170126870 magId "2170126870" @default.
• W2170126870 workType "article" @default.